Evaluation of the Effect of Muscle Activity on Subjective Tinnitus in Temporomandibular Disorders

Treatment of Temporomandibular Joint Disorder can help reduce subjective tinnitus levels. This treatment changes the electrical activity of the patient's chewing muscles. For this reason, the relationship between muscular change and tinnitus levels can be evaluated.

Study Overview

• Status: Completed
• Conditions: Tinnitus, Subjective; Temporomandibular Disorder
• Intervention / Treatment: Procedure: Occlusal Splint Treatment- Non Invasive treatment

Detailed Description

The study will be conducted with patients who routinely apply to Kütahya Health Sciences University Faculty of Dentistry. 70 patients with temporomandibular disease accompanied by tinnitus and bruxism will be included in the study. Demographic data such as age, gender, and systemic disease, drug and trauma history data will be collected.

TMD findings of the patients will be classified according to Wilkes classification. The Wilkes classification is as follows:

1. Stage 1 (early period): No pain or limitation of jaw movements, only reciprocal click during or after chewing. Mild anterior disc displacement in radiological evaluation.
2. Stage 2 (early/intermediate): Mild to moderate pain with reciprocal clicking and periodic locking. Change in disc position.
3. Stage 3 (intermediate): Joint tenderness with frequent pain. Ongoing crash. On the radiological image, changes in disc position and deformation with adhesions.
4. Stage 4 (intermediate/late): Chronic pain that gets worse from time to time and limitation in jaw movements. Change in the shape and position of the disc and the shape of the condyle. Multiple adhesions with hard tissue changes.
5. Stage 5 (late stage): pain that occurs from time to time with crepitation.

Bruxism data (time of onset, whether it is felt during the day/night, fatigue, difficulty in opening the mouth in the morning, stressful period) are questioned and examination findings (disc displacement, masseter hypertrophy on inspection, linea alba, attrition of teeth, fractures in restorations and teeth, muscle and joint pain) , facial asymmetry, mouth opening) will be recorded. The characteristics of tinnitus (objective/subjective, duration, in which ear, increasing and decreasing factors, type) and hearing loss, vertigo will be questioned.

Patients will be divided into two groups. Group I will consist of Wilkes Stage 1-2 patients with temporomandibular intra-articular disorder. Group II will consist of patients with both Wilkes Stage 1-2 temporomandibular intra-articular disorder and bruxism.

In order to measure the muscle strength of the patients before the treatment, EMG containing right-left M. Masseters will be taken in order to easily reach the chewing muscles and to minimize the patient's discomfort. The analog EMG signal will be amplified using a differential amplifier with a high common-mode rejection ratio (bandwidth 5 KHz, peak-to-peak input range 200 μV). The average of the signals is over 500 ms. (Micromed, Italy)

Superficial EMG will be taken following the following protocol:

To reduce skin impedance, the skin will be cleaned before electrode placement and recordings will be made after 5-6 minutes.

Superficial electrodes will be placed on the right and left masseter muscles, with the upper pole of the electrode parallel to the intersection between the tragus-labial commissura and the exocantion-gonion lines. The grounding electrode will be placed in the forehead area.

For all tests, patients will be seated with their head unsupported and asked to maintain a natural upright position.

To avoid any effects of fatigue, a rest period of at least 3 minutes will be allowed between tests. The average EMG potential for each of the muscles will be set to 100%.

To standardize EMG potentials, two 10 mm thick cotton rolls will be placed on each subject's mandibular first and second molars, and maximum voluntary clamping of 5 seconds will be recorded. For 5 seconds, the patient will be encouraged to maintain the same level of contraction. EMG data analysis for all tests, the best 3-s period (the one with the most stable signal) will be automatically selected by the software and used for all subsequent analysis.

Electromyographic activity will then be recorded with a maximum voluntary squeeze at the intercuspal position; The patient will be invited to squeeze as hard as possible and maintain the same level of contraction for 5 seconds. Electromyographic activity will also be taken again while the patient is at rest.

For each subject, the EMG potentials of the analyzed muscles recorded during the maximum voluntary clamping tests will be expressed as a percentage of the average potential recorded during the standardization test (maximum voluntary clamping on cotton rolls).

(μV/μV×100). To assess muscle symmetry, the EMG waves of the masseter muscles will then be compared by calculating a percent overlap coefficient (POC, %). POC is an index of the symmetrical distribution of muscle activity determined by occlusion. The index ranges from 0% to 100%: a POC of 100% will be achieved when two paired muscles contract with perfect symmetry.

Tinnitus and bruxism will be evaluated by the patient with the VAS score. Tinnitus level will additionally be measured with the Tinnitus Handicap Inventory. Then, an occlusal splint will be prepared for the patients. It will be recommended to use them for 24 weeks. Postoperative EMG, Tinnitus Handicap Inventory and VAS scores will be re-evaluated after the use of the occlusal splint.

The obtained data beam when; Age, gender, disease findings, preoperative and postoperative Tinnitus Handicap Inventory and VAS scores, masseter and temporal muscle strength in EMG will be compared and evaluated.

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Kütahya, Turkey, 43100
    • Kutahya Health Science University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients older than 18 years
• Patients with chronic subjective tinnitus
• Patients with Wilkes Stage 1-2

Exclusion Criteria:

• Patients with Wilkes Stage 3-4-5
• Patients with tinnitus due to audiological, neurological, metabolic or pathological reasons
• Patients with objective tinnutus
• Patients with normal tinnitus
• Mentally retarded patients
• Hearing loss, use of ototoxic drugs
• Those with ear diseases such as acute ostitis media, perforated tympanic membrane
• Those with Meniere's disease
• Patients with middle ear pathology
• Those with intracranial pathology
• Those with traumatic cervical spine injury
• Patients with severe depression diagnosed by a psychologist
• Patients who have received TMB treatment in the last two months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: TMD Wilkes Stage I-II and Subjective Tinnitus; Patients with subjective tinnitus and temporomandibular disorder. It was treated with an occlusal splint.	Procedure: Occlusal Splint Treatment- Non Invasive treatment; Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.
Active Comparator: TMD Wilkes Stage I-II, Subjective Tinnitus and Bruxism; Patients with subjective tinnitus and temporomandibular disorder and bruxism. It was treated with an occlusal splint.	Procedure: Occlusal Splint Treatment- Non Invasive treatment; Each patient in the study had temporomandibular disorder. The first-line routine treatment of this disease is an occlusal splint. This treatment was applied to each patient. Surgical intervention was not performed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Masseters Activity	To evaluate the symmetry and electrical activity of masseters by surface EMG	6th months

Collaborators and Investigators

• Sponsor: Kutahya Health Sciences University
• Investigators: Principal Investigator: Elif Çoban, DDS, https://avesis.ksbu.edu.tr/elif.coban/iletisim; Principal Investigator: Mehmet Ç. Ulucan, DDS, https://avesis.ksbu.edu.tr/mehmetcagatay.ulucan; Principal Investigator: Selver S. Başak, DDS, https://avesis.ksbu.edu.tr/selversuna.basak; Principal Investigator: Berceste Güler, DDS, https://avesis.ksbu.edu.tr/berceste.guler; Principal Investigator: Merve Akdeniz Leblebiciler, MD, https://avesis.ksbu.edu.tr/merve.akdenizleblebicier; Principal Investigator: Vural Kavuncu, MD, https://avesis.ksbu.edu.tr/vural.kavuncu

Study record dates

Study Major Dates

• Study Start (Actual): December 21, 2021
• Primary Completion (Actual): June 21, 2022
• Study Completion (Actual): December 21, 2022

Study Registration Dates

• First Submitted: March 16, 2023
• First Submitted That Met QC Criteria: April 24, 2023
• First Posted (Actual): April 26, 2023

Study Record Updates

• Last Update Posted (Actual): April 26, 2023
• Last Update Submitted That Met QC Criteria: April 24, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Joint Diseases; Musculoskeletal Diseases; Muscular Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases; Ear Diseases; Sensation Disorders; Jaw Diseases; Hearing Disorders; Craniomandibular Disorders; Mandibular Diseases; Myofascial Pain Syndromes; Temporomandibular Joint Disorders; Temporomandibular Joint Dysfunction Syndrome; Tinnitus; Anti-Infective Agents; Dermatologic Agents; Antifungal Agents; Keratolytic Agents; Salicylic Acid
• Other Study ID Numbers: 2021-09/07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No